SenesTech Q3 revenue misses estimates

Reuters
Nov 11
SenesTech Q3 revenue misses estimates

Overview

  • SenesTech Q3 revenue grows 43% yr/yr but misses analyst expectations

  • Adjusted EBITDA loss improves

  • Evolve product sales grow 77% yr/yr, driving revenue growth

Outlook

  • Company expects accelerated growth across e-commerce sites

  • Company anticipates additional municipal deployments underway or planned

  • SenesTech intends to pursue profitable growth moving forward

Result Drivers

  • EVOLVE PRODUCT SALES - Evolve Rodent Birth Control products grew 77% yr/yr, now 85% of total revenue

  • E-COMMERCE GROWTH - E-commerce revenue increased 55% yr/yr, driven by growth in Amazon sales

  • MUNICIPAL DEPLOYMENT - Municipal revenue grew 139% yr/yr due to expanded deployments in NYC and Chicago

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$690,000

$730,000 (1 Analyst)

Q3 Net Income

Beat

-$1.30 mln

-$1.64 mln (1 Analyst)

Q3 Income From Operations

Beat

-$1.35 mln

-$1.58 mln (1 Analyst)

Q3 Basic EPS

-$0.28

Q3 Gross Profit

$433,000

Q3 Operating Expenses

$1.78 mln

Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • The average consensus recommendation for the agricultural chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Senestech Inc is $10.00, about 66.1% above its November 7 closing price of $3.39

Press Release: ID:nPn8x94Bva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10